Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Nov;113(3):869–876. doi: 10.1111/j.1476-5381.1994.tb17073.x

Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.

V Richard 1, N Kaeffer 1, M Hogie 1, C Tron 1, T Blanc 1, C Thuillez 1
PMCID: PMC1510467  PMID: 7858879

Abstract

1. Previous studies suggested that endothelin-1 (ET-1) may play a role in myocardial ischaemia and reperfusion. This study was designed to test the effect of a new nonpeptide antagonist of endothelin ETA and ETB receptors, bosentan, on myocardial infarct size, ventricular arrhythmias, and coronary endothelial dysfunction after ischaemia and reperfusion. 2. Anaesthetized male Wistar rats were subjected to 20 min ischaemia (left coronary artery occlusion) followed by 1 h (for the evaluation of coronary endothelial dysfunction) or 2 h (for the evaluation of infarct size) reperfusion, or 5 min ischaemia followed by 15 min reperfusion (for the evaluation of reperfusion arrhythmias). Vascular studies were performed on 1.5-2 mm coronary segments (internal diameter 250-300 microns) removed distal to the site of occlusion and mounted in wire myographs for isometric tension recording. Area at risk and infarct size were determined by Indian ink injection and triphenyl tetrazolium staining, using computerized analysis of enlarged sections after colour video acquisition. 3. Bosentan, administered at a dose which virtually abolished the pressor response to big ET-1 (3 mg kg-1, i.v. before ischaemia) did not affect heart rate, arterial pressure or the rate pressure product before ischaemia, during ischaemia and during reperfusion. Bosentan did not affect the incidence of reperfusion-induced ventricular fibrillation (controls: 86%, n = 14; bosentan: 93%, n = 15), and did not modify infarct size (% of area at risk: controls: 63 +/- 4, n = 10; bosentan: 60 +/- 6, n = 8).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
870

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando K., Hirata Y., Shichiri M., Emori T., Marumo F. Presence of immunoreactive endothelin in human plasma. FEBS Lett. 1989 Mar 13;245(1-2):164–166. doi: 10.1016/0014-5793(89)80213-3. [DOI] [PubMed] [Google Scholar]
  2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  3. Bird J. E., Waldron T. L. Incomplete inhibition of endothelin-1 pressor effects by an endothelin ETA receptor antagonist. Eur J Pharmacol. 1993 Aug 24;240(2-3):295–298. doi: 10.1016/0014-2999(93)90912-2. [DOI] [PubMed] [Google Scholar]
  4. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  5. Clozel M., Breu V., Gray G. A., Löffler B. M. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S377–S379. doi: 10.1097/00005344-199322008-00099. [DOI] [PubMed] [Google Scholar]
  6. Dauber I. M., VanBenthuysen K. M., McMurtry I. F., Wheeler G. S., Lesnefsky E. J., Horwitz L. D., Weil J. V. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res. 1990 Apr;66(4):986–998. doi: 10.1161/01.res.66.4.986. [DOI] [PubMed] [Google Scholar]
  7. Donckier J., Hanet C., Stoleru L., Van Mechelen H., Galanti L., Hayashida W., Keyeux A., Ketelslegers J. M., Pouleur H. Effects of endothelin-1 at pathophysiologic concentrations on coronary perfusion and mechanical function of normal and postischemic myocardium. J Cardiovasc Pharmacol. 1994 Feb;23(2):212–219. [PubMed] [Google Scholar]
  8. Ezra D., Goldstein R. E., Czaja J. F., Feuerstein G. Z. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol. 1989 Jul;257(1 Pt 2):H339–H343. doi: 10.1152/ajpheart.1989.257.1.H339. [DOI] [PubMed] [Google Scholar]
  9. Flavahan N. A. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992 May;85(5):1927–1938. doi: 10.1161/01.cir.85.5.1927. [DOI] [PubMed] [Google Scholar]
  10. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol. 1991 Aug;103(4):2009–2015. doi: 10.1111/j.1476-5381.1991.tb12368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grover G. J., Sleph P. G., Fox M., Trippodo N. C. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther. 1992 Dec;263(3):1074–1082. [PubMed] [Google Scholar]
  12. Hearse D. J., Richard V., Yellon D. M., Kingma J. G., Jr Evolving myocardial infarction in the rat in vivo: an inappropriate model for the investigation of drug-induced infarct size limitation during sustained regional ischaemia. J Cardiovasc Pharmacol. 1988 Jun;11(6):701–710. [PubMed] [Google Scholar]
  13. Hori S., Kyotani S., Inoue S., Fukuda K., Ohnishi Y., Kusuhara M., Aikawa N., Yamaguchi K., Nakamura Y., Handa S. Subepicardial microischemia formation induced by epicardial application of endothelin-1. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S300–S301. doi: 10.1097/00005344-199100177-00085. [DOI] [PubMed] [Google Scholar]
  14. Larkin S. W., Clarke J. G., Keogh B. E., Araujo L., Rhodes C., Davies G. J., Taylor K. M., Maseri A. Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. Am J Cardiol. 1989 Oct 15;64(14):956–958. doi: 10.1016/0002-9149(89)90855-2. [DOI] [PubMed] [Google Scholar]
  15. Lechleitner P., Genser N., Mair J., Maier J., Artner-Dworzak E., Dienstl F., Puschendorf B. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem. 1993 Jun;39(6):955–959. [PubMed] [Google Scholar]
  16. Li Y. W., Whittaker P., Kloner R. A. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am Heart J. 1992 Feb;123(2):346–353. doi: 10.1016/0002-8703(92)90645-c. [DOI] [PubMed] [Google Scholar]
  17. Li Y., Kloner R. A. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation. 1993 May;87(5):1642–1648. doi: 10.1161/01.cir.87.5.1642. [DOI] [PubMed] [Google Scholar]
  18. Liu J., Chen R., Casley D. J., Nayler W. G. Ischemia and reperfusion increase 125I-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol. 1990 Mar;258(3 Pt 2):H829–H835. doi: 10.1152/ajpheart.1990.258.3.H829. [DOI] [PubMed] [Google Scholar]
  19. Liu Y., Downey J. M. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol. 1992 Oct;263(4 Pt 2):H1107–H1112. doi: 10.1152/ajpheart.1992.263.4.H1107. [DOI] [PubMed] [Google Scholar]
  20. Liu Y., Downey J. M. Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein. Cardiovasc Res. 1993 Apr;27(4):608–611. doi: 10.1093/cvr/27.4.608. [DOI] [PubMed] [Google Scholar]
  21. McMurdo L., Corder R., Thiemermann C., Vane J. R. Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 1993 Feb;108(2):557–561. doi: 10.1111/j.1476-5381.1993.tb12840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McMurdo L., Thiemermann C., Vane J. R. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol. 1994 May;112(1):75–80. doi: 10.1111/j.1476-5381.1994.tb13032.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Miyauchi T., Doi T., Suzuki N., Kakihana M., Yamaguchi I., Sugishita Y., Mitsui T., Hori M., Masaki T., Goto K. Plasma endothelin-1 concentrations in the coronary sinus in dogs with artificially induced myocardial infarction. Peptides. 1992 Sep-Oct;13(5):1013–1015. doi: 10.1016/0196-9781(92)90064-a. [DOI] [PubMed] [Google Scholar]
  24. Miyauchi T., Yanagisawa M., Tomizawa T., Sugishita Y., Suzuki N., Fujino M., Ajisaka R., Goto K., Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989 Jul 1;2(8653):53–54. doi: 10.1016/s0140-6736(89)90303-6. [DOI] [PubMed] [Google Scholar]
  25. Moravec C. S., Reynolds E. E., Stewart R. W., Bond M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun. 1989 Feb 28;159(1):14–18. doi: 10.1016/0006-291x(89)92397-8. [DOI] [PubMed] [Google Scholar]
  26. Mulvany M. J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977 Jul;41(1):19–26. doi: 10.1161/01.res.41.1.19. [DOI] [PubMed] [Google Scholar]
  27. Neubauer S., Ertl G., Pulzer F., Haas U., Hirsch A., Zimmermann S., Kochsiek K. Effects of endothelin-1 in the isolated heart under ischemic and cardioplegic conditions. J Cardiovasc Pharmacol. 1990 Nov;16(5):804–811. doi: 10.1097/00005344-199011000-00017. [DOI] [PubMed] [Google Scholar]
  28. Neubauer S., Zimmermann S., Hirsch A., Pulzer F., Tian R., Bauer W., Bauer B., Ertl G. Effects of endothelin-1 in the isolated heart in ischemia/reperfusion and hypoxia/reoxygenation injury. J Mol Cell Cardiol. 1991 Dec;23(12):1397–1409. doi: 10.1016/0022-2828(91)90186-p. [DOI] [PubMed] [Google Scholar]
  29. Nyborg N. C., Mikkelsen E. O. 5-Hydroxytryptamine does not release endothelium-derived relaxing factor in rat isolated coronary arteries. Eur J Pharmacol. 1990 Sep 21;186(2-3):295–300. doi: 10.1016/0014-2999(90)90447-e. [DOI] [PubMed] [Google Scholar]
  30. Pearson P. J., Schaff H. V., Vanhoutte P. M. Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries. Circ Res. 1990 Aug;67(2):385–393. doi: 10.1161/01.res.67.2.385. [DOI] [PubMed] [Google Scholar]
  31. Pearson P. J., Schaff H. V., Vanhoutte P. M. Long-term impairment of endothelium-dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation. 1990 Jun;81(6):1921–1927. doi: 10.1161/01.cir.81.6.1921. [DOI] [PubMed] [Google Scholar]
  32. Prieto D., Benedito S., Nyborg N. C. Heterogeneous involvement of endothelium in calcitonin gene-related peptide-induced relaxation in coronary arteries from rat. Br J Pharmacol. 1991 Jul;103(3):1764–1768. doi: 10.1111/j.1476-5381.1991.tb09860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Qiu S., Théroux P., Marcil M., Solymoss B. C. Plasma endothelin-1 levels in stable and unstable angina. Cardiology. 1993;82(1):12–19. doi: 10.1159/000175848. [DOI] [PubMed] [Google Scholar]
  34. Reimer K. A., Jennings R. B., Cobb F. R., Murdock R. H., Greenfield J. C., Jr, Becker L. C., Bulkley B. H., Hutchins G. M., Schwartz R. P., Jr, Bailey K. R. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ Res. 1985 May;56(5):651–665. doi: 10.1161/01.res.56.5.651. [DOI] [PubMed] [Google Scholar]
  35. Richard V., Kaeffer N., Tron C., Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation. 1994 Mar;89(3):1254–1261. doi: 10.1161/01.cir.89.3.1254. [DOI] [PubMed] [Google Scholar]
  36. Richard V., Tron C., Thuillez C. Ischaemic preconditioning is not mediated by oxygen derived free radicals in rats. Cardiovasc Res. 1993 Nov;27(11):2016–2021. doi: 10.1093/cvr/27.11.2016. [DOI] [PubMed] [Google Scholar]
  37. Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992 Mar;13(3):103–108. doi: 10.1016/0165-6147(92)90038-8. [DOI] [PubMed] [Google Scholar]
  38. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  39. Salvati P., Chierchia S., Dho L., Ferrario R. G., Parenti P., Vicedomini G., Patrono C. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol. 1991 Jun;17(6):1007–1014. doi: 10.1097/00005344-199106000-00022. [DOI] [PubMed] [Google Scholar]
  40. Seo B., Oemar B. S., Siebenmann R., von Segesser L., Lüscher T. F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994 Mar;89(3):1203–1208. doi: 10.1161/01.cir.89.3.1203. [DOI] [PubMed] [Google Scholar]
  41. Shah A. M., Lewis M. J., Henderson A. H. Inotropic effects of endothelin in ferret ventricular myocardium. Eur J Pharmacol. 1989 Apr 25;163(2-3):365–367. doi: 10.1016/0014-2999(89)90208-2. [DOI] [PubMed] [Google Scholar]
  42. Stewart D. J., Kubac G., Costello K. B., Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991 Jul;18(1):38–43. doi: 10.1016/s0735-1097(10)80214-1. [DOI] [PubMed] [Google Scholar]
  43. Tippins J. R., Antoniw J. W., Maseri A. Endothelin-1 is a potent constrictor in conductive and resistive coronary arteries. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S177–S179. doi: 10.1097/00005344-198900135-00048. [DOI] [PubMed] [Google Scholar]
  44. Tsao P. S., Aoki N., Lefer D. J., Johnson G., 3rd, Lefer A. M. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation. 1990 Oct;82(4):1402–1412. doi: 10.1161/01.cir.82.4.1402. [DOI] [PubMed] [Google Scholar]
  45. Tsuji S., Sawamura A., Watanabe H., Takihara K., Park S. E., Azuma J. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. 1991;48(18):1745–1749. doi: 10.1016/0024-3205(91)90211-s. [DOI] [PubMed] [Google Scholar]
  46. VanBenthuysen K. M., McMurtry I. F., Horwitz L. D. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest. 1987 Jan;79(1):265–274. doi: 10.1172/JCI112793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Vemulapalli S., Rivelli M., Chiu P. J., del Prado M., Hey J. A. Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs. J Pharmacol Exp Ther. 1992 Sep;262(3):1062–1069. [PubMed] [Google Scholar]
  48. Wagner O. F., Christ G., Wojta J., Vierhapper H., Parzer S., Nowotny P. J., Schneider B., Waldhäusl W., Binder B. R. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992 Aug 15;267(23):16066–16068. [PubMed] [Google Scholar]
  49. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  50. Watanabe Y., Naruse M., Monzen C., Naruse K., Ohsumi K., Horiuchi J., Yoshihara I., Kato Y., Nakamura N., Kato M. Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S503–S505. doi: 10.1097/00005344-199100177-00143. [DOI] [PubMed] [Google Scholar]
  51. Yasuda M., Kohno M., Tahara A., Itagane H., Toda I., Akioka K., Teragaki M., Oku H., Takeuchi K., Takeda T. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990 Apr;119(4):801–806. doi: 10.1016/s0002-8703(05)80315-1. [DOI] [PubMed] [Google Scholar]
  52. Yellon D. M., Alkhulaifi A. M., Browne E. E., Pugsley W. B. Ischaemic preconditioning limits infarct size in the rat heart. Cardiovasc Res. 1992 Oct;26(10):983–987. doi: 10.1093/cvr/26.10.983. [DOI] [PubMed] [Google Scholar]
  53. Yorikane R., Koike H. The arrhythmogenic action of endothelin in rats. Jpn J Pharmacol. 1990 Jun;53(2):259–263. doi: 10.1254/jjp.53.259. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES